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Okayama University research: Cell injections get to the heart of congenital defects 
(Okayama, 28 January 2015) Researchers at Okayama University and Okayama University 
Hospital show that children suffering from a condition known as hypoplastic left heart 
syndrome (HLHS) experienced some improvement in cardiac function in the months 
following injection of CDCs. 
Children suffering from a lethal congenital heart defect may benefit from injections of a 
type of stem cells – cardiosphere-derived cells (CDCs). A study conducted by researchers at 
Okayama University and Okayama University Hospital showed that children suffering from a 
condition known as hypoplastic left heart syndrome (HLHS) experienced some improvement 
in cardiac function in the months following injection of CDCs. 
The left ventricle, aorta and related valvular components in the hearts of HLHS patients are 
underdeveloped, with not enough cells being produced. Children born with the condition 
may die if they do not receive immediate medical attention. They require surgery within a 
few days of birth and additional treatment is needed long-term to deal with the right-
ventricular-dependent circulation.   
Previous studies had suggested that loss of a type of stem cell – progenitor cells which can 
differentiate into a range of other cells – is responsible for lower replication of the heart 
muscle cells. In their report of the research the Okayama researchers highlight that cardiac 
progenitor cells in children are “more abundant, self-renewing, and multipotent than those 
found in adults,” and propose their use as a safe therapeutic strategy for patients with heart 
failure. 
The researchers monitored the heart functions in both a group of 7 patients that had 
received cell injection and a control group of 7 patients who had not. As they conclude, “Our 
prospective controlled study, the first paediatric phase 1 clinical trial of stem cell therapy for 
heart disease to our knowledge, suggests that intracoronary infusion of autologous cardiac 
progenitor cells is a feasible and safe approach to treat children with HLHS.” 
Background 
Cardiosphere-derived cells 
Tissue-specific stem progenitor cells can be found in the adult mammalian heart. When 
cloned in suspension they form cardiospheres. The patient-derived CDCs used in the study 
were tested prior to use to confirm expression of cardiac transcription factors and normal 
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chromosomes to avoid tumour formation after injection. Transcoronoray Injection was 
successfully achieved in all patients with no adverse effects. 
Cardiac function monitoring 
The heart functions monitored by the researchers included right ventricular ejection fraction 
(RVEF), end-systolic volume (volume of blood at the maximum contraction point, ESV), and 
end-diastolic volume (volume of blood when at the maximum filling point, EDV), stroke 
volume and cardiac output. In addition the levels a type of peptide - brain natriuretic 
peptide (BNP) were monitored. These peptides are secreted by the ventricles of the heart in 
response to excessive stretching of the heart muscle cells.  
Many of the parameters measured showed improvements in the group that had received 
CDCs. In particular RVEF levels improved from 36.1 ± 7.5% at baseline to 42.7% ± 8.7% at 12 
months. BNP levels were decreased 18 months after CDC injection compared with controls 
((26.3 ± 28.5 pg/mL vs. 68.6 ± 42.4 pg/mL).  
The researchers associated the decrease in heart failure status in CDC-treated patients with 
the decrease in BNP levels 18 months after CDC compared with the controls. In addition, 
right ventricular wall masses had decreased significantly and tissue growth was improved 
suggesting long term benefits 3-18m months after CDC injection. 
Study conclusions and limitations 
Due to the rarity of the disease and the difficulty in recruiting a sample population the study 
was small and non-randomized. With groups of just 7 patients the size of the study may 
limit the ability to draw definite conclusions as to the safety and effectiveness of the using 
CDC injections to treat HLHS patients. However the improved RVEP 18 months after CDC 
CDC injection provides a positive proof of concept for the treatment. 
Further studies are required to endorse the results. In addition the cell biological 
mechanisms for enhancing cardiac function are still not understood and a prognostic cell-
tracking system may be required as new translational medicine for children. 
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Figure 1.  Angiographic images of transcoronary infusion of CDCs into children with HLHS. 
(A) Primary coronary angiography was performed prior to the CDC infusion. A 5 French 
guiding catheter Launcher (Medtronic) was placed in the hypoplastic ascending aorta, which 
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was connected to the newly reconstructed aortic arch by the Norwood procedure. Selective 
CDC transfer was performed into right (B), left ascending (C), and left circumferential (D) 
coronary arteries by a stop-flow technique (arrows). (E) Hand injection of contrast medium 
demonstrates that the coronary arteries were unobstructed after CDC infusion. 
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Okayama University Medical Research Updates （OU-MRU） 
Vol.1：Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells 
from blood samples for genetic testing 
Vol.2：Ensuring a cool recovery from cardiac arrest 
Vol.3：Organ regeneration research leaps forward 




















About Okayama University 
Okayama University is one of the largest 
comprehensive universities in Japan with 
roots going back to the Medical Training  
Place sponsored by the Lord of Okayama  
and established in 1870. Now with 1,300 
faculty and 14,000 students, the University 
offers courses in specialties ranging from 
medicine and pharmacy to humanit ies  
a n d  p h y s i c a l  s c i e n c e s .  O k a y a m a  
University is located in the heart of Japan 
approximately 3 hours west of Tokyo by  
Shinkansen. 
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